Structured Review

Biocare Medical ccnd1
Level of pEGFR, EGFR and <t>CCND1</t> protein in bladder tumors by genotype. Intensity of bladder tumor cells staining positively for pEGFR, EGFR and CCND1 is graphed by genotype for the EGFR_05 SNP. Staining intensity was scored on a scale of 0–4 by a single pathologist.
Ccnd1, supplied by Biocare Medical, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccnd1/product/Biocare Medical
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
ccnd1 - by Bioz Stars, 2020-07
92/100 stars

Images

1) Product Images from "EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis"

Article Title: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis

Journal: Carcinogenesis

doi: 10.1093/carcin/bgp077

Level of pEGFR, EGFR and CCND1 protein in bladder tumors by genotype. Intensity of bladder tumor cells staining positively for pEGFR, EGFR and CCND1 is graphed by genotype for the EGFR_05 SNP. Staining intensity was scored on a scale of 0–4 by a single pathologist.
Figure Legend Snippet: Level of pEGFR, EGFR and CCND1 protein in bladder tumors by genotype. Intensity of bladder tumor cells staining positively for pEGFR, EGFR and CCND1 is graphed by genotype for the EGFR_05 SNP. Staining intensity was scored on a scale of 0–4 by a single pathologist.

Techniques Used: Staining

2) Product Images from "EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis"

Article Title: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis

Journal: Carcinogenesis

doi: 10.1093/carcin/bgp077

Level of pEGFR, EGFR and CCND1 protein in bladder tumors by genotype. Intensity of bladder tumor cells staining positively for pEGFR, EGFR and CCND1 is graphed by genotype for the EGFR_05 SNP. Staining intensity was scored on a scale of 0–4 by a single pathologist.
Figure Legend Snippet: Level of pEGFR, EGFR and CCND1 protein in bladder tumors by genotype. Intensity of bladder tumor cells staining positively for pEGFR, EGFR and CCND1 is graphed by genotype for the EGFR_05 SNP. Staining intensity was scored on a scale of 0–4 by a single pathologist.

Techniques Used: Staining

3) Product Images from "EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis"

Article Title: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis

Journal: Carcinogenesis

doi: 10.1093/carcin/bgp077

Level of pEGFR, EGFR and CCND1 protein in bladder tumors by genotype. Intensity of bladder tumor cells staining positively for pEGFR, EGFR and CCND1 is graphed by genotype for the EGFR_05 SNP. Staining intensity was scored on a scale of 0–4 by a single pathologist.
Figure Legend Snippet: Level of pEGFR, EGFR and CCND1 protein in bladder tumors by genotype. Intensity of bladder tumor cells staining positively for pEGFR, EGFR and CCND1 is graphed by genotype for the EGFR_05 SNP. Staining intensity was scored on a scale of 0–4 by a single pathologist.

Techniques Used: Staining

Related Articles

Modification:

Article Title: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis
Article Snippet: .. This risk modification is biologically plausible since VEGF is a critical factor in angiogenesis, which feeds tumor growth, while CCND1 regulates the rate of division of the cells in the tumor. .. VEGF expression in bladder tumors has been linked to tumor progression ( , ).

Staining:

Article Title: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis
Article Snippet: .. To examine potential genotype–phenotype relationships, we stained 12 paraffin-embedded tumors with antibodies to EGFR (clone EGFR.113; Novocastra Laboratories, Newcastle, UK), phospho-EGFR and CCND1 (CP236A; Biocare Medical, Walnut Creek, CA), as described previously, and included both positive and negative controls ( ). ..

other:

Article Title: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis
Article Snippet: There were no significant independent effects of the SNPs tested in VEGF, EGF or CCND1.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Biocare Medical cyclin d1
    Representative strong positive immunohistochemical staining, labeled with Diaminobenzidine, for (a) epidermal growth factor receptor (×100), (b) p53 (×40) (c) Bcl2 (×100), (d) vascular endothelial growth factor (×100), (e) cyclooxygenase-2 (×100), (f) <t>cyclin</t> D1 (×40), (g) human epidermal receptor-2 (×400), (h) Ki-67 (×100)
    Cyclin D1, supplied by Biocare Medical, used in various techniques. Bioz Stars score: 92/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cyclin d1/product/Biocare Medical
    Average 92 stars, based on 11 article reviews
    Price from $9.99 to $1999.99
    cyclin d1 - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    Image Search Results


    Representative strong positive immunohistochemical staining, labeled with Diaminobenzidine, for (a) epidermal growth factor receptor (×100), (b) p53 (×40) (c) Bcl2 (×100), (d) vascular endothelial growth factor (×100), (e) cyclooxygenase-2 (×100), (f) cyclin D1 (×40), (g) human epidermal receptor-2 (×400), (h) Ki-67 (×100)

    Journal: Journal of Carcinogenesis

    Article Title: Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma

    doi: 10.4103/1477-3163.139450

    Figure Lengend Snippet: Representative strong positive immunohistochemical staining, labeled with Diaminobenzidine, for (a) epidermal growth factor receptor (×100), (b) p53 (×40) (c) Bcl2 (×100), (d) vascular endothelial growth factor (×100), (e) cyclooxygenase-2 (×100), (f) cyclin D1 (×40), (g) human epidermal receptor-2 (×400), (h) Ki-67 (×100)

    Article Snippet: In an age < 40 years, EGFR, Bcl2, VEGF, cox-2, cyclin D1 were overexpressed, while p53 and HER-2 were overexpressed in the age group > 40 years.

    Techniques: Immunohistochemistry, Staining, Labeling

    Kaplan–Meier curves for overall survival according to the biomarker overexpression (epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2) and clinicpathological factors (stage and tumor differentiation)

    Journal: Journal of Carcinogenesis

    Article Title: Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma

    doi: 10.4103/1477-3163.139450

    Figure Lengend Snippet: Kaplan–Meier curves for overall survival according to the biomarker overexpression (epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2) and clinicpathological factors (stage and tumor differentiation)

    Article Snippet: In an age < 40 years, EGFR, Bcl2, VEGF, cox-2, cyclin D1 were overexpressed, while p53 and HER-2 were overexpressed in the age group > 40 years.

    Techniques: Biomarker Assay, Over Expression

    Nuclear accumulation of GSK-3β is associated with the loss of pancreatic cancer differentiation. A, distribution of GSK-3β staining patterns in PanIN lesions and pancreatic carcinomas. B to E, immunohistochemical staining of serial sections from the same metastatic lymph node shows accumulation of GSK-3β ( B ), NF-κB p65 ( C ), and cyclin D1 ( D ) in nuclei of cancer cells, whereas β-catenin ( E ) shows membranous staining.

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3? in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation

    doi: 10.1158/1078-0432.CCR-06-0196

    Figure Lengend Snippet: Nuclear accumulation of GSK-3β is associated with the loss of pancreatic cancer differentiation. A, distribution of GSK-3β staining patterns in PanIN lesions and pancreatic carcinomas. B to E, immunohistochemical staining of serial sections from the same metastatic lymph node shows accumulation of GSK-3β ( B ), NF-κB p65 ( C ), and cyclin D1 ( D ) in nuclei of cancer cells, whereas β-catenin ( E ) shows membranous staining.

    Article Snippet: Cyclin D1 and NF-κB nuclear accumulation was defined as positive staining of > 10% of cancer cell nuclei throughout the tumor. β-Catenin expression was defined as any of three patterns: ( a ) membranous expression, similar to that in normal pancreatic ductal cells, ( b ) loss of membranous staining, signified by a loss of membranous expression found in > 50% of cancer cells, and ( c ) nuclear accumulation, defined as staining of > 10% of cancer cell nuclei throughout the tumor.

    Techniques: Staining, Immunohistochemistry